News and Trends 3 Nov 2025 AAVantgarde closes $141 million series B round to tackle inherited eye diseases Today AAvantgarde closes a $141 million series B round to advance its inherited eye diseases pipeline; find out more about its approach! November 3, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Aug 2025 Five biotech companies in South Korea you should know about Discover five South Korean biotechs that have received funding in recent years and are broadening R&D in various therapeutics areas. August 26, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 16 Jul 2025 Eight rare autoimmune diseases biotechs are fighting to treat Discover eight rare autoimmune diseases you may not have heard of and what biotechs are doing to treat them. July 16, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 11 Jun 2025 Can gene therapy treat vision loss? Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness. June 11, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Dec 2024 Six biotech companies leading the way in India Discover six of the top biotech companies in India, which is currently brimming with biotechs and a young, skilled workforce. December 30, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 25 Dec 2024 When biotech makes Christmas miracles a reality Explore how biotech breakthroughs in 2024 have changed lives, bringing real Christmas miracles to patients and offering hope for the future. December 25, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 26 Jul 2024The first mass-market cell therapy? Listen to our conversation with CEO Greg Kunst about how Aurion’s treatment could be the first mass-market cell therapy available July 26, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 17 May 2024Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotides German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Isarna Therapeutics’s lead compound, ISTH0036, is in […] May 17, 2024 Share WhatsApp Twitter Linkedin Email
In Depth 22 Nov 2023 Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […] November 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2023 Allgenesis says dry eye patients’ trial data ‘encouraging’ Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, has announced topline data from its phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of dry eye disease (DED). AG-80308 was considered safe at all doses […] June 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2023 Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including Oxford Science Enterprises, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take Beacon Therapeutics’ development candidates […] June 12, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Jun 2023 Five ophthalmology biotech companies to look out for There are hundreds of different eye diseases, with some of the most common major eye diseases including age-related macular degeneration (AMD) – an age-related eye disease that can blur central vision – glaucoma – a condition where the optic nerve becomes damaged – and diabetic retinopathy (DR) – a complication of diabetes in which high […] June 1, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email